2017 MOYAD + SCHOLZ MID-YEAR UPDATE RECAP

By Alexandra "Xan" Oakley, PCRI Educational Writer

The 2017 Moyad + Scholz Mid-Year Update was an incredible and enlightening experience. Conferences hosted by the PCRI are created to provide education, empowerment, and support for all attendees. This year, patients and caregivers came together to learn the most recent, accurate information on prostate cancer, have the opportunity to ask questions directly to speakers, and find a peaceful environment to interact with others who understand their situation.

This conference featured Drs. Dreicer and Rossi. Robert Dreicer, MD, from Cleveland Clinic, gave an in-depth presentation on advanced prostate cancer. Carl Rossi, MD, from Scripps Proton Therapy Center, provided exceptional information on radiation therapy, proton therapy, and salvage radiation after failed radiation. Mark Scholz, MD, PCRI’s executive director and a medical oncologist, spoke on active surveillance for men with newly diagnosed prostate cancer and covered many issues that surround new diagnosis. Mark Moyad, MD, from the University of Michigan Medical Center (and PCRI’s entertainer extraordinaire), spoke about diet and nutrition and moderated all the proceedings.

The conference was filled with crucial information helpful to a broad range of prostate cancer patients. Like all of PCRI’s conferences, it also provided the additional benefit of a positive environment for attendees to find encouragement and feel free to ask questions in a safe space, a place for coming together to be mutually empowered. The eagerness to learn and the surrounding support at these conferences is a vibrant force! I can confidently speak for everyone at PCRI when I say that we are grateful to play a role in these events and to advocate for the men and caregivers we serve. For anyone who was not able to attend, you can purchase the DVD online for a donation of $50.


Previous
Previous

On Stress: Thoughts from Mark & Mia Moyad

Next
Next

Surgery Versus Radiation in High-Risk Prostate Cancer